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Although the dispositions of many antibiotics are altered in cystic fibrosis patients, that of vancomycin has
not been studied. To assess vancomycin pharmacokinetics, 10 adult cystic fibrosis patients were given a
parenteral dose of vancomycin (15 mg/kg) during the first 72 h of hospitalization for acute bronchopulmonary
exacerbation. Blood samples were obtained at 0, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 15, and 24 h. The mean (standard
deviation) weight, measured creatinine clearance, and Taussig clinical score were 51 (13) kg, 130 (39) ml/min/
1.73 m2, and 64 (13), respectively. Multicompartmental pharmacokinetic parameters were best described by a
two-compartment model. The mean (standard deviation) volume of distribution, total body clearance, and
terminal elimination rate constant were 0.58 (0.15) liter/kg, 91 (19) ml/min/1.73 m2, and 0.123 (0.05) h21,
respectively. These values were consistent with vancomycin pharmacokinetic parameters obtained in previous
studies of healthy adult volunteers. Vancomycin dosages predicted by using a two-compartment Bayesian
model were approximately 15 mg/kg every 8 to 12 h. There were poor correlations between clinical score or
creatinine clearance and any pharmacokinetic parameter (r values of <0.32). The coefficient of correlation
between urine flow rate and total body clearance was 0.7 (P < 0.05). Adult cystic fibrosis patients exhibit a
disposition of vancomycin similar to that exhibited by healthy adults, and thus cystic fibrosis does not alter
vancomycin pharmacokinetics.
Antibiotic pharmacokinetics in patients with cystic fibrosis
(CF) have been extensively studied, because of the frequent
use of antibiotics to manage acute bronchopulmonary exacer-
bations and because of the altered drug disposition in these
patients (6). CF patients often require higher dosages of many
antibiotics to achieve concentrations in serum similar to those
in non-CF patients; however, it is uncertain whether this is a
function of the disease itself, i.e., because CF patients are
typically younger with normal renal function and have en-
hanced hepatic metabolism of drugs (11), or is because of the
more aggressive dosing required with the antibiotics typically
used to treat gram-negative respiratory infections. Although
there are conflicting studies, the pharmacokinetics of some
antibiotics, such as ciprofloxacin, trimethoprim-sulfamethox-
azole, ceftazidime, and aminoglycosides, appear to be altered
in CF patients, whereas the pharmacokinetics of certain other
antibiotics, such as imipenem-cilastatin, do not appear to be
altered (6). Consequently, it should not be assumed that the
pharmacokinetics of all antibiotics are altered in CF patients.
Although pseudomonal species are the predominant bacte-
ria in the respiratory tracts of CF patients, Staphylococcus
aureus may be present. In CF patients, S. aureus strains cul-
tured from the respiratory tract are usually susceptible to me-
thicillin, with a reported incidence of methicillin resistance of
approximately 3% (1, 3). Treatment of methicillin-susceptible
staphylococcal infections in CF patients has been traditionally
accomplished with beta-lactams such as nafcillin or cephalo-
sporins.
Vancomycin is a glycopeptide antibiotic typically used for
the treatment of moderate to severe infections due to methi-
cillin-resistant staphylococci and for the treatment or prophy-
laxis of gram-positive aerobic infections in patients allergic to
beta-lactams. For CF patients, the most likely clinical situa-
tions in which vancomycin may be used are (i) the treatment of
staphylococcal infections of the respiratory tract in penicillin-
allergic patients, (ii) the treatment of infections involving in-
dwelling central intravenous catheters, in which Staphylococcus
epidermidis, often resistant to beta-lactams, is a common cause,
and (iii) for patients receiving home intravenous (i.v.) therapy
for staphylococcal infections, in which frequently administered
drugs such as nafcillin (every 4 h), are not practical and the
longer dosing interval of vancomycin would be desirable. To
our knowledge, the pharmacokinetics of vancomycin in CF
patients has not been previously studied. Because of the al-
tered drug disposition often encountered in CF patients and
the potential benefits of vancomycin, we examined the phar-
macokinetics of vancomycin in a group of adult CF patients
experiencing acute bronchopulmonary exacerbations.
(This work was presented at the North American Cystic
Fibrosis Conference, Washington, D.C., 1992, and the Amer-
ican Society of Hospital Pharmacists Midyear Clinical Meet-
ing, Orlando, Fla., 1992.)
MATERIALS AND METHODS
Adult (18 years or older) CF patients admitted for acute bronchopulmonary
exacerbation to either Duke University Medical Center or the University of
North Carolina at Chapel Hill Hospitals were eligible for entry into the study.
The patients had been previously diagnosed with CF on the basis of positive
sweat chloride tests and clinical history. The study was approved by both insti-
tutions’ investigational review boards, and written informed consent was ob-
tained from each subject prior to entry into the study. Acute bronchopulmonary
exacerbation was defined as the presence of at least 5 of the following 10 clinical,
laboratory, or radiologic findings, according to published criteria (24): (i) change
in volume, appearance, or color of sputum; (ii) increased respiratory rate; (iii)
progressive findings on chest ascultation; (iv) increased cough; (v) new infiltrates
on chest roentgenogram; (vi) decreased appetite or recent weight loss; (vii) fever,
defined as an oral temperature of greater than 38.38C; (viii) leukocytosis with a
left shift; (ix) decreased exercise tolerance and fatigue; and (x) deterioration in
pulmonary function tests from baseline levels.
Patients were excluded if they were pregnant as determined by a urine preg-
nancy test, had a known hypersensitivity to vancomycin, were admitted to an
intensive care unit, had received parenteral vancomycin or aminoglycosides
within 3 weeks prior to admission, were participating in another drug study, had
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elevated liver function tests (transaminase or bilirubin test result greater than
twice the normal level), or had a baseline serum creatinine level of greater than
1.4 mg/dl. Following entry into the study, each patient was evaluated by a
pulmonologist and assigned a disease severity score based on two clinical prog-
nostic scoring methods, the Shwachman score (23) and the Taussig score (25),
and a chest radiographic scoring method (the Brasfield score) (4). Patients were
recruited so that there was a range of disease severity, with one-half of the
subjects having Taussig scores of less than 60 and the other subjects having scores
above this value.
A single dose of i.v. vancomycin was administered to each study subject within
72 h after admission to the hospital. A manufacturer’s single lot of vancomycin
(Vancocin; Eli Lilly, Indianapolis, Ind.) was used for each patient at a dose of
approximately (rounded to the nearest 50 mg) 15 mg/kg, on the basis of total
body weight. The dose was reconstituted according to the guidelines of the
manufacturer and diluted with 5% glucose in water in an evacuated glass bottle
to yield a final concentration of 5 mg/ml. The total vancomycin dose prepared
was in excess of the actual dose to allow for drug loss during priming of i.v. tubing
and to account for drug remaining in the i.v. tubing at the end of the i.v. infusion.
These steps were taken to ensure that the prescribed dose was the same as the
actual dose administered to the patient. With the exception of one individual, the
study patients did not receive vancomycin for therapeutic purposes; rather, they
received it simply for study purposes. The patients received other antibiotics,
such as aminoglycosides and antipseudomonal beta-lactams, as usually pre-
scribed for acute exacerbations. Each dose of vancomycin was infused over 1 h
with a single, calibrated volumetric infusion pump (Abbott Lifecare; Abbott
Laboratories, Chicago, Ill.). The study patients were pretreated with hydroxyzine
(50 mg orally) approximately 0.5 h prior to initiation of the vancomycin dose to
prevent development of ‘‘red-man’s syndrome.’’
Twelve blood samples were obtained, at around the time of the vancomycin
dose (0 h) and at 1.0, 1.25, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12.0, 15.0, and 24.0 h after
initiation of the vancomycin infusion. Blood samples were obtained from the arm
contralateral to the arm used for drug administration. Previously placed indwell-
ing central i.v. lines were used only when drug administration and blood sampling
were not performed through the same lumen (e.g., drug administration through
a central catheter and blood sampling through a peripheral i.v. access). The i.v.
access was flushed with an amount of fluid adequate to ensure that no vanco-
mycin remained in the catheter. A 24-h urine collection beginning with initiation
of the vancomycin infusion was obtained to determine creatinine clearance
(CLCR). Each subject voided just prior to, during, and at the completion of the
24-h period. CLCR was normalized to body surface area. Body surface area was
calculated by the method of DuBois and DuBois (7).
Blood samples were harvested and frozen at 2208C within 2 h after collection
and analyzed in duplicate within 72 h. The mean of the two analyses was used as
the reported concentration. A fluorescence polarization immunoassay (TDx;
Abbott Laboratories Diagnostics Div., Irving, Tex.) was used to determine van-
comycin concentrations. The interday assay precisions were 4.9, 2.1, and 3.9% for
the controls with low, medium, and high concentrations, respectively. The lower
limit of detection for the assay is 1 mg/ml.
Pharmacokinetic parameters were determined by standard methods. Serum
vancomycin concentrations were fit to a multicompartment model, initially by
using RSTRIP (8) to obtain initial estimates of parameters and then by using a
computerized nonlinear regression analysis program (PCNONLIN) (14). The
area under the serum concentration-time curve (AUC) was determined by the
log trapezoidal rule and extrapolated to infinity (AUC0–`) by dividing the last
measurable serum concentration by the terminal elimination rate constant esti-
mated from PCNONLIN. The volume of distribution at steady state (Vss) was
determined by the equation Vss 5 [(dose)(AUMC)]/(AUC)2, where AUMC is
the area under the first moment of the serum concentration-time curve. A
correction was made for the infusion by subtracting [(t/2) 3 (dose/AUC)] from
the Vss values, where t is the duration of the infusion. Total body clearance (CL)
was calculated by the formula CL 5 dose/AUC0–`.
A Bayesian pharmacokinetic computer program (Abbott Pharmacokinetics
System; Abbott Diagnostics Division) was used to estimate vancomycin dosing
requirements. Pharmacokinetic values derived from PCNONLIN (Vc, K12, and
K21) were used to determine predicted dosages by the Bayesian program with a
two-compartment model. Target steady-state concentrations were 1-h-postinfu-
sion peaks of 30 to 40 mg/ml and troughs of 5 to 10 mg/ml. For purposes of
comparison, a one-compartment model utilizing the method of Sawchuk et al.
(22), a commonly used method in clinical practice, was also used to predict
dosage requirements, targeting similar steady-state peak and trough concentra-
tions. For this method, the volume of distribution and elimination rate constant
were calculated by using the 1-h-postinfusion peak and the lowest detectable
concentration in serum (usually that of the 15-h sample) and were then used to
predict doses.
Statistical analysis involved analysis of the correlations between severity of
disease and pharmacokinetic parameters (Vss, CL, and terminal elimination rate
constant), between CLCR and CL, and between urine flow rate and CL. The
Mann-Whitney nonparametric t test was used to compare the values for non-
compartmental parameters (Vss and CL) obtained for the CF study subjects with
those obtained for normal volunteers in studies by Healy et al. (10) and Golper
et al. (9).
RESULTS
The demographic characteristics of the 10 patients who par-
ticipated in this study are shown in Table 1. Upon enrollment
into the study, 90% of the patients had sputum changes, 50%
had an increased respiratory rate, 40% had progressive find-
ings on chest ascultation, 100% had increased cough, 30% had
new infiltrates on chest roentgenogram, 70% had leukocytosis
with a shift to the left, 80% had weight loss and decreased
appetite, 70% had decreased exercise tolerance and fatigue,
50% had a deterioration in pulmonary function tests, and 40%
had fever. One subject (patient 4) initially received vancomycin
therapeutically (1 g i.v. every 12 h) for sepsis due to S. aureus,
which probably was associated with an indwelling central ve-
nous catheter. The other nine patients received vancomycin
solely for study purposes to determine vancomycin pharmaco-
kinetics.
The pharmacokinetic data obtained from PCNONLIN for
each subject are shown in Table 2. A two-compartment model
provided the best computer fit on the basis of the Aikake
TABLE 1. Patient characteristicsa
Characteristic Value
No. male/no. female.......................................... 4/6
Age (yr) .............................................................. 27.16 6.7 (21–38)
Wt (kg) ............................................................... 51.26 12.8 (32–76)
Body surface area (m2)..................................... 1.51 6 0.21 (1.19–1.91)
Taussig score...................................................... 63.66 12.9 (44–85)
Shwachman score .............................................. 61.56 17.0 (35–90)
Brasfield score.................................................... 14.26 5.1 (5–22)
FEV1 (liters)...................................................... 1.196 0.44 (0.65–1.90)
Albumin (g/100 ml) ........................................... 3.66 0.3 (3.1–4.1)
Measured CLCR (ml/min/1.73 m
2) .................. 130 6 39 (88–187)
Vancomycin dose (mg) ..................................... 723 6 129 (450–900)






a Unless otherwise indicated, values are expressed as means 6 standard devi-
ations, with the range given in parentheses.









1 1.3 0.1196 0.506 107.0
2 1.47 0.1352 0.345 67.0
3 2.12 0.1891 0.516 80.4
4 1.73 0.0782 0.631 73.5
5 0.92 0.1475 0.463 91.2
6 2.14 0.1224 0.669 81.3
7 2.0 0.1364 0.707 103.8
8 2.15 0.1510 0.513 78.1
9 1.71 0.2377 0.530 131.0
10 0.41 0.0525 0.857 100.0
Mean (SD) 1.60 (0.6) 0.123 (0.05) 0.58 (0.15) 91.0 (19)
Coefficient of
variation (%)
37.5 40.7 25.8 20.8
a Pharmacokinetic data derived from PCNONLIN by using all vancomycin
concentration values and a two-compartment model.
b Distribution rate constant.
c Terminal elimination rate constant.
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criterion (8), although a three-compartment model was best
for three subjects. Two-compartment data were subsequently
reported for all subjects. The results of dosing predictions
obtained by using the Bayesian pharmacokinetic computer
program for each subject are shown in Table 3. When the
method of Sawchuk et al. (22) was used to calculate vancomy-
cin pharmacokinetic parameters and dosages, the mean vol-
ume of distribution, terminal elimination rate constant, and
doses were 0.6 liter/kg, 0.177 h21, and 15.9 mg/kg (with dosing
intervals of every 8 h for four subjects and every 12 h for six
subjects), respectively. Serum vancomycin concentration data
(means and standard deviations) for all subjects are shown in
Fig. 1.
The results of analysis of correlations between pharmacoki-
netic parameters and patient parameters showed weak corre-
lations between CL and CLCR (r5 0.34), CL and Taussig score
(r5 20.28), and CL and Shwachman score (r5 20.26). There
was a stronger relationship between CL and urine flow rate
(r 5 0.70; P , 0.05). All r values from analysis of the correla-
tion between Vss and CLCR or prognostic scores were less than
0.3.
Adverse effects due to vancomycin were observed in three
patients. Two patients received hydroxyzine approximately 30
min prior to vancomycin, and the third patient refused the
hydroxyzine. One patient experienced marked erythema and
pruritis approximately 10 min into the infusion. The symptoms
began to resolve over the next 30 min despite continuation of
the vancomycin, but it was 24 h before the erythema disap-
peared. The second and third patients experienced a milder
erythema and pruritis of the scalp. The second patient, who
was pretreated with hydroxyzine, had resolution of symptoms
after 20 min, whereas the patient who had refused pretreat-
ment required several hours before the pruritis abated. None
of the three subjects had decreases in blood pressure associ-
ated with the apparent red-man’s syndrome. None of the symp-
toms were judged severe enough to necessitate discontinuation
of the vancomycin infusion.
DISCUSSION
Parenteral vancomycin is sometimes employed to manage
bacterial infections due to gram-positive aerobes in CF pa-
tients (particularly with methicillin-resistant organisms), in
penicillin-allergic patients, and in the home health care setting.
When we examined the disposition of vancomycin in 10 adult
CF patients, we found that the pharmacokinetics of vancomy-
cin did not differ from those in healthy adults or other patient
populations reported in the literature.
The principal question in pharmacokinetic studies with CF
patients is often whether the dosage requirements for a par-
ticular antibiotic are different than those with non-CF patients.
Table 4 summarizes the results of studies of vancomycin phar-
macokinetics in healthy adult volunteers (2, 9, 10) as well as
patients with various disease states (13, 18–20). The determi-
nation of pharmacokinetic parameters, assay methodology,
and serum sampling strategies in these studies were similar to
those in our study, and thus the studies should be comparable.
The Vss and CL were essentially the same in our study patients
and the normal healthy volunteers. In fact, an examination of
the data reported for each of 11 subjects by Healy et al. (10)









1 0.580 0.1510 16.6, every 12 h
2 0.500 0.1278 14.0, every 12 h
3 0.480 0.2090 21.0, every 8 h
4 0.450 0.0770 13.9, every 12 h
5 0.440 0.1280 15.0, every 12 h
6 0.500 0.1870 20.1, every 12 h
7 0.510 0.2010 16.4, every 12 h
8 0.410 0.3140 19.2, every 8 h
9 0.450 0.1640 15.4, every 8 h
10 0.580 0.1500 17.9, every 12 h
Mean (SD) 0.490 (0.057) 0.171 (0.06) 16.9 (2.5)
a Doses were calculated so as to achieve peaks of 30 to 40 mg/ml and troughs
of 5 to 10 mg/ml by using a computerized Bayesian program (Abbott Pharma-
cokinetics System).
FIG. 1. Serum vancomycin concentration-versus-time curve for 10 adult CF patients. The vertical lines represent one standard deviation.
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and 9 subjects by Golper et al. (9) showed that there was no
statistical difference between our CF patients and the normal
volunteers (Mann-Whitney test). In all of the studies of pa-
tients except that of Matzke et al. (13), the Vss and CL are
similar to those reported in our study. Thus, the pharmacoki-
netics of vancomycin in adult CF patients does not appear to
be substantially different from that observed in other patient
groups with relatively normal renal function or in normal
healthy adults.
The correlation between pharmacokinetic parameters and
patient characteristics (prognostic scores and CLCR) was poor
in most instances. However, there was a strong correlation
between urine flow rate and CL for vancomycin in our study.
An examination of the relationship between CL and urine flow
rate was prompted by the extremely rapid drug elimination in
one patient who ingested very large amounts of water during
the study day. It has been reported that renal clearance does
not account for all of the elimination of vancomycin from the
body, indicating potentially significant nonrenal elimination
(12). A good correlation between vancomycin clearance and
urine flow rate suggests that vancomycin may be reabsorbed,
and consequently, an increase in urine flow rate would result in
a decrease in drug reabsorption and thus in increased elimi-
nation from the kidney via glomerular filtration. However, one
study has indicated that vancomycin renal clearance is in-
versely related to urine flow rate (9). Further study would be
necessary to more clearly determine if this relationship be-
tween urine flow and vancomycin clearance in CF patients
exists.
The manufacturer recommends a vancomycin dose of 15
mg/kg every 12 h (or 7.5 mg/kg every 6 h) in patients with
normal renal function. Dosage predictions obtained by using
both a Bayesian two-compartment computer program and the
more simplified one-compartment method of Sawchuk et al.
(22) indicated that a vancomycin dosage of ;15 mg/kg every 8
to 12 h appears to be appropriate. After completion of this
study, of the first 10 CF patients at Duke University Medical
Center who received vancomycin therapeutically, 8 patients
received vancomycin dosages of approximately 15 mg/kg every
12 h and 2 patients required every-8-h dosing to achieve ther-
apeutic concentrations. One approach may be to use a 12-h
dosing interval for mildly to moderately ill adult CF patients
with normal renal function and an 8-h dosing interval for
severely ill patients with normal renal function or those previ-
ously requiring every-8-h dosing and then to determine con-
centrations in serum to verify the appropriateness of the dosing.
There is controversy in the literature regarding the need to
monitor blood vancomycin concentrations (5, 15). The manu-
facturer of vancomycin recommends monitoring concentra-
tions in blood for patients with decreased renal function, the
elderly, severely ill patients, and patients receiving nephrotox-
ins concurrently (17). The typical CF patient experiencing an
acute bronchopulmonary exacerbation is treated with a 10- to
14-day course of an aminoglycoside plus another antipseudo-
monal antibiotic. Although aminoglycoside nephrotoxicity is
rare in patients with CF, ototoxicity does occur (16). The effect
of combining both agents on ototoxicity in CF patients is un-
known but could justify the monitoring of blood vancomycin
concentrations. Another potential reason to monitor blood
vancomycin levels is because our study suggests that dosages
higher than those recommended by the manufacturer are nec-
essary for some CF patients, although these dosages are prob-
ably not different from those appropriate for other young adult
patients with good renal function.
The adverse effects from vancomycin experienced by three
CF patients in this study were consistent with red-man’s syn-
drome. These reactions occurred in two patients despite pre-
treatment with an antihistamine. The incidence of red-man’s
syndrome from vancomycin has not been previously reported
for CF patients. The incidence in this study may be relatively
high because of red-man’s syndrome being more likely to occur
with the first dose (21). We did not evaluate the effect of
vancomycin on hearing but no patient reported any symptoms
of tinnitus or apparent hearing loss.
In summary, the results of this study indicate that adult CF
patients appear to have a vancomycin disposition similar to
that of healthy adult volunteers as well as adult patients with
normal renal function who have various disease states. A dos-
age of 15 mg/kg every 8 to 12 h appears to be an appropriate
initial vancomycin dosage in adult CF patients with normal
renal function.
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